Medical Weight Loss: What Physician-Guided Treatment Looks Like

Definition

What Medical Weight Loss Actually Is

Medical weight loss treats obesity as the chronic, relapsing, multi-system disease it is — defined by the American Medical Association in 2013 and consistent with current National Heart, Lung, and Blood Institute guidance. It is not a wellness trend, a 30-day cleanse, or a single prescription.

A program qualifies as medical when a board-certified physician owns the diagnosis, the treatment plan, and the ongoing monitoring. That includes deciding whether medication is appropriate at all, which medication and at what dose, what to measure, how often to reassess, and what the maintenance plan looks like after the loss phase ends.

Workup

What a Real Baseline Looks Like

Before any prescription, a physician-led program runs a comprehensive baseline: weight history, family history, current medications, comorbidity screen, blood pressure, waist circumference, and labs that typically include CBC, comprehensive metabolic panel, HbA1c or fasting glucose with insulin, lipid panel, TSH, liver enzymes, vitamin D, and hormone panels where indicated (testosterone in men; estradiol, FSH, progesterone, DHEA-S, and cortisol patterns in women with suspected hormonal weight gain).

Body composition is assessed at baseline — ideally via DEXA, or via clinical-grade bioimpedance — so future change can be measured against the right numbers (fat mass, lean mass, visceral adipose). A scale alone is not a body-composition measurement.

Medications

Choosing the Right Medication

Medication selection depends on indication, magnitude of loss needed, comorbidities, insurance, tolerance, and cost. The major options:

• ·Semaglutide 2.4 mg (Wegovy) — FDA-approved for chronic weight management; ~14.9% mean loss in STEP 1.
• ·Tirzepatide (Zepbound) — FDA-approved for chronic weight management and OSA; ~20.9% mean loss at the 15 mg dose.
• ·Oral semaglutide (newer 25 mg formulation) — for patients who cannot or will not inject.
• ·Liraglutide 3 mg (Saxenda) — older daily injectable, useful in selected scenarios.
• ·Phentermine/topiramate, naltrexone/bupropion — non-incretin oral options for specific patient profiles.

Medication is one component, not the program.

Nutrition & Training

Protecting Lean Mass While Losing Fat

Any rapid weight loss costs lean mass. Without protective interventions, 25–40% of weight lost on GLP-1 therapy can be lean tissue — which damages metabolic rate, function, and the durability of the result.

The protective protocol is unglamorous and effective: protein at 1.2–1.6 g/kg of goal body weight per day, adequate fiber and micronutrients, hydration, and 2–3 weekly sessions of progressive resistance training. A registered dietitian and a credentialed trainer or physical therapist are part of the program, not an upsell.

Monitoring

What Gets Measured (and How Often)

Weekly: weight, side-effect check, hydration and nutrition compliance, training adherence.

Monthly during titration: dose decision based on tolerability and response (not the calendar alone).

Quarterly: body composition (DEXA or bioimpedance), blood pressure, waist circumference, and repeat key labs (HbA1c, CMP, lipid panel, hormones where indicated).

Annually: full metabolic and cardiovascular reassessment and revision of the long-term plan.

Maintenance

What Happens After the Loss Phase

Maintenance is the part most programs ignore — and where most patients regain. Options include continuing the same medication at the loss dose, stepping down to a maintenance dose, transitioning to a different agent, or — for a minority of well-selected patients — a structured discontinuation with intensified nutrition and training support.

A real medical weight loss program plans the maintenance phase before the loss phase ends. That is the difference between treating a disease and treating a number on the scale.